MiMedx Group announced that the publication of its peer-reviewed scientific study, which proves the link between the properties of its CollaFix fibers and beginning of tendon regeneration.
Here are four key takeaways:
1. The study, called "Cyclic Tension Promotes Fibroblastic Differentiation of Human MSCs Cultured on Collagen-Fibre Scaffolds," was published online in the Journal of Tissue Engineering and Regenerative Medicine.
2. The study found that fibrous, braided collagen scaffolds are excellent candidates for use with a cyclic culture bioreactor. They help prime mesenchymal stem cells for cell-based therapies in tendon and ligament repair; as well as produce tissue-engineered alternatives to current tendon/ligament tissue grafts.
3. The company's proprietary product, CollaFix, a collagen-fiber scaffold was created by wet spinning sub-millimeter fibers from purified soluble collagen and crosslinking these fibers.
4. Worldwide, the MiMedx's CollaFix technologies are protected with 24 patents. Currently, in the U.S. and internationally, there are more than 30 patent applications pending covering the technology.